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The success of Candida albicans as a major human fungal pathogen is dependent on its ability to colonize and
survive as a commensal on diverse mucosal surfaces. One trait required for survival and virulence in the host
is the morphogenetic yeast-to-hypha transition. Mds3 was identified as a regulator of pH-dependent morpho-
genesis that functions in parallel with the classic Rim101 pH-sensing pathway. Microarray analyses revealed
that mds3/ cells had an expression profile indicative of a hyperactive TOR pathway, including the prefer-
ential expression of genes encoding ribosomal proteins and a decreased expression of genes involved in
nitrogen source utilization. The transcriptional and morphological defects of the mds3/ mutant were
rescued by rapamycin, an inhibitor of TOR, and this rescue was lost in strains carrying the rapamycin-
resistant TOR1-1 allele or an rbp1/ deletion. Rapamycin also rescued the transcriptional and morphological
defects associated with the loss of Sit4, a TOR pathway effector, but not the loss of Rim101 or Ras1. The sit4/
andmds3/mutants had additional phenotypic similarities, suggesting that Sit4 and Mds3 function similarly
in the TOR pathway. Finally, we found that Mds3 and Sit4 coimmunoprecipitate. Thus, Mds3 is a new member
of the TOR pathway that contributes to morphogenesis in C. albicans as a regulator of this key morphogenetic
pathway.
Eukaryotic cell growth and morphogenesis is affected by
numerous environmental signals. These environmental signals
are integrated by highly conserved regulators, including Ras,
protein kinase C (PKC), and the target of rapamycin (TOR).
These regulators govern the activity of signal transduction
pathways, which generally promote changes in gene expression
affecting an appropriate cellular response to the environmental
signal. TOR is an essential kinase conserved throughout eu-
karyotic evolution. In mammalian systems, mTOR is required
for embryogenesis (38) and for cellular morphogenesis in neu-
rons (33), vacuolar smooth-muscle cells (53), and T cells (19).
In the model yeast Saccharomyces cerevisiae, TOR plays a funda-
mental role in morphogenesis, being required for pseudohyphal
growth and sporulation (14, 80). TOR governs morphogenesis
by regulating numerous biological processes, including auto-
phagy, translation, and ribosome biogenesis (79). Thus, in eu-
karyotic cells, TOR responds to environmental signals to pro-
mote growth and morphogenetic changes.
In the fungal opportunistic pathogen Candida albicans, the
most well-studied morphogenetic transition is the yeast-hypha
switch. The switch between the yeast and hyphal growth
forms plays a critical role in the ability of C. albicans to
colonize as a commensal and cause disease as a pathogen.
Yeast cells are small, are nonadherent, and are less immu-
nogenic and divide more rapidly than hyphal cells, which
may allow C. albicans to successfully outcompete the faster-
growing bacterial flora and the immune responses as well as
pass through capillary beds during disseminated disease. Hy-
phal cells are long and extremely adherent, promote profound
immune responses, and divide more slowly. Further, hyphal
cells secrete numerous degradative enzymes and are invasive
(32, 56). Hyphal cells may allow C. albicans to maintain itself
on mucosal surfaces and, in immunocompromised hosts, enter
the bloodstream. Both yeast and hyphal cells are observed in
commensally colonized and diseased sites, demonstrating the
relevance of this morphogenetic switch for C. albicans survival
in the host. This idea is further supported by genetic analyses
demonstrating that C. albicans mutants locked in a yeast or
filamentous form are unable to cause disease (48, 58). Thus,
the yeast-hypha morphogenetic switch is critical for pathogen-
esis.
Because the yeast-hypha transition is critical for pathogenic-
ity, much work has been devoted to identifying the environ-
mental sensors and signal transduction pathways that respond
to these signals. The yeast-hypha morphogenetic switch is gov-
erned by a plethora of environmental cues, including pH, nu-
trient availability, temperature, and host factors (3, 10, 17, 56).
For example, neutral-alkaline environmental pH is sensed by
the Rim101 signal transduction pathway, resulting in the pro-
teolytic activation of the Rim101 transcription factor, which
promotes hyphal formation (16, 62, 63). Loss-of-function mu-
tants in the Rim101 pathway do not form hyphae in response
to neutral-alkaline environmental pH and show reduced viru-
lence in animal models of infection (15, 61). Similarly, nutrient
levels are sensed by the TOR pathway, which also promotes
hyphal formation and is required for pathogenesis (4, 14, 46).
These studies highlight the profound link between morphogen-
esis and virulence in the host in response to environmental
signals, such as pH and starvation.
To gain further insights into C. albicans adaptation to envi-
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ronmental pH, we identified additional signal transduction
pathways that contribute to adaptation to environmental pH.
For example, calcineurin and its associated transcription fac-
tor, Crz1, were found to act in parallel with Rim101 for adap-
tation to alkaline pH in C. albicans (43). Further, using a
forward genetics approach, MDS3 was identified as a positive
regulator of alkaline pH responses in C. albicans (18). Like
calcineurin, Mds3 was shown to act in parallel to Rim101 to
promote neutral-alkaline pH responses. Mds3 also governs
adaptation to neutral-alkaline pH responses in S. cerevisiae;
however, this function originally was masked by the presence
of the redundant Mds3 paralog, Pmd1. While the well-studied
Rim101 pathway is required for adaptation to environmental
pH, Mds3 plays a key role in adaptation to environmental pH.
MDS3 originally was identified in S. cerevisiae as a positive
regulator of meiosis, a morphogenetic process that requires an
alkaline environment (5, 24). In C. albicans, Mds3 is involved
in a variety of morphogenetic processes, including the yeast-
hyphal transition, chlamydospore formation, and biofilm for-
mation (18, 60, 65). Despite a clear role for Mds3 in diverse
morphogenetic processes in fungi, how Mds3 promotes mor-
phogenesis is unknown. Work done in S. cerevisiae suggested
that Mds3 transmits starvation signals to Ras (5, 54). However,
we demonstrate that Mds3 contributes to morphogenesis in C.
albicans through the negative regulation of the TOR pathway.
We find that an mds3/ mutant has transcriptional defects
indicative of a hyperactive TOR pathway and that these tran-
scriptional defects are rescued by rapamycin, a TOR pathway
inhibitor. Further, the filamentation defects associated with
the mds3/ mutant are rescued by rapamycin. We also dem-
onstrate that the loss of Sit4, a downstream effector of TOR,
mimics the loss of Mds3. In C. albicans, the loss of Sit4 or Mds3
results in resistance to rapamycin, whereas in S. cerevisiae this
loss results in sensitivity to rapamycin, suggesting that TOR
functions are distinct in these two species. Finally, we demon-
strate that Mds3 and Sit4 interact, suggesting a mechanism of
TOR pathway regulation. In total, our results establish that
Mds3 is a member of the TOR pathway and suggest that Mds3
regulates C. albicans development and morphogenesis through
the TOR pathway.
MATERIALS AND METHODS
C. albicans strains and plasmids. All yeast strains used in this study are listed
in Table 1. DAY938 was constructed by deleting the second copy of MDS3
from VIC1, the MDS3/mds3::ARG4 parent of strain VIC3 (18), using an
mds3::URA3-dpl200 disruption cassette amplified with primers MDS3 5DR and
MDS3 3DR (Table 2). Strains DAY1122 and DAY1123 were constructed by
transforming strains DAY938 and DAY286, respectively, with the tor1::HIS1
disruption cassette, which was amplified using primers TOR1 5DR and TOR1
3DR (Table 2). All deletions are from the start to the stop codon and were
generated by chemical transformation (78). The correct integration of the dis-
ruption cassettes was verified by PCR using the Mds3null 5-detect and Mds3null
3-detect primers or TOR1 5detect-2 and TOR1 3detect primers (Table 2).
DAY1118 and DAY1119 were generated by transforming DAY938 with the
PmeI-digested plasmids pDDB343 and pDDB353, respectively.
Strains DAY1120, DAY1121, DAY1124, DAY1125, and DAY1321, which
contain the TOR1-1 allele, were generated as previously described, with minor
modifications (13). Briefly, primers TOR1 A-C and TOR1 A-C Rev (Table 2)
were annealed and used for transformation. Transformants were selected on
yeast extract-peptone-dextrose (YPD) supplemented with 100 nM rapamycin.
Rapamycin-resistant clones were screened by the NheI digestion of a PCR
product amplified with primers JOHE6247 and JOHE6248 and were verified by
sequencing (13). DAY1255 then was generated by transforming DAY1120 with
PmeI-digested pDDB343. The correct genotype of all of the mutants carrying
TOR1-1 and/or tor1::HIS1 alleles was verified by the Southern blotting of the
NheI/NcoI or NheI/PvuII digestion of genomic DNA (data not shown) and using
PCR products amplified with primers TOR1 probe 5 and TOR1 probe 3 or
TOR1 probe 5-2 and TOR1 probe 3 as probes (Table 2). The probes were
radiolabeled with [-32P]dCTP using the Prime-a-Gene labeling system (Pro-
mega).
The mds3/ sit4/ mutant DAY1233 was constructed by sequentially
deleting both MDS3 alleles from the sit4/ strain DAY972, using the
mds3::URA3-dpl200 disruption cassette amplified with the primers MDS3 5DR
and MDS3 3DR described above. The URA3-dpl200 marker was recycled by
growing the cells in synthetic complete (SC) medium supplemented with 5-fluo-
roorotic acid (5-FOA).
The mds3/ rbp1/ mutant DAY1239 was constructed by sequentially de-
leting both MDS3 alleles from the rbp1/ strain DAY1230. Strain DAY1230
was generated by recycling the MX3::URA3R::MX3 marker in strain DAY1223
(13) in 5-FOA. The mds3::URA3-dpl200 disruption cassette was amplified with
primers MDS3 5DR and MDS3 3DR described above, and the URA3-dpl200
marker was recycled by growing the cells in 5-FOA.
DAY1234, which contains a functional SIT4–c-Myc allele, was constructed by
introducing a C-terminal MYC-TADH1-URA3 cassette. The MYC-TADH1-URA3
cassette was PCR amplified with primers Sit4 MYC Nter 5 and Sit4 MYC
URA3 Nter 3 from plasmid pDDB372 (pMG1095 [30]) (Table 2). The correct
integration of the cassette was verified by PCR using primers 5 Myc detect and
Sit4 3 detect (Table 2) and by Western blotting using anti-Myc antibody (R950-
25; Invitrogen).
To construct the strains for the coimmunoprecipitation studies, DAY1234 was
transformed with NheI-digested pDDB499 (MDS3-HA) to generate strain
DAY1236. DAY1234 also was transformed with PmeI-digested pDDB353 (un-
tagged MDS3 vector) to generate the control strain DAY1235.
The MDS3 complementation vector pDDB353 was constructed as follows.
Plasmid pDDB343 was generated by replacing the NruI restriction site in
pDDB78 with a PmeI site. Primers DDB78 PmeIxNruI 5 and DDB78 PmeIx-
NruI 3 were annealed and used for the gap repair of the NruI-digested pDDB78
through in vivo recombination in trp mutant S. cerevisiae strain L40 to generate
plasmid pDDB343. Wild-type MDS3 sequence with flanking promoter and ter-
minator sequences was amplified in two high-fidelity PCRs (Pfu turbo DNA
polymerase; Stratagene) using primer pairs MDS3 5comp new and MDS3
5-2comp new as well as MDS3 3comp new-2 and MDS3 3-2comp new-2 from
strain BWP17 genomic DNA (Table 2). Both PCR products were transformed
with EcoRI/NotI-double digested pDDB343 into strain L40 to produce plasmid
pDDB353 through in vivo recombination. The complete open reading frame
(ORF) of MDS3 was verified by sequencing.
The MDS3-HA-tagged vector DDB499 was constructed as follows. To find a
location in MDS3’s ORF that could be tagged without affecting Mds3 function,
we performed the random mutagenesis of MDS3 using the GPS-LS linker scan-
ning system (New England BioLabs). An NheI/AhdI fragment from plasmid
DDB353 containing MDS3 and its flanking regions was cloned into an NheI/
AhdI-digested pGEM-T Easy vector (Promega), pDDB407, to generate plasmid
pDDB408. pDDB408 was used as the substrate for random Tn7 insertion mu-
tagenesis. Plasmids carrying Tn7 integrations within MDS3’s ORF were screened
by PCR using primer S and primer N (Promega), MDS3null 5-detect, and
MDS3null 3-detect (Table 2). The Tn7 transposon was excised, and plasmids
were religated, leaving a 15-bp insertion that contains a PmeI site. Plasmids
containing mutated versions of MDS3’s ORF were AhdI/NdeI digested, sub-
cloned into NotI/EcoRI-digested pDDB409 by in vivo recombination, and tested
for the complementation of an mds3/ mutant. Plasmid pDDB500, containing
a 5-amino-acid insertion at amino acid 1051, was selected for hemagglutinin
(HA) tagging. The HA tag was PCR amplified from plasmid pDDB369
(pMG1921 [30]) using primers MDS3-HA 56 5 and MDS3-HA 56 3 (Table 2)
and in vivo recombined into the PmeI-digested plasmid pDDB500 using S.
cerevisiae L40 strain to generate pDDB499, which inserts HA after residue 1056.
pDDB499 rescued the mds3/ mutant, indicating that Mds3 tolerated the
addition of the 29 amino acids of the 3 HA tag.
Plasmid pDDB409 was constructed by replacing the unique NruI site in
pDDB78 with a 26-bp linker containing NgoMIV-KpnI-NheI restriction sites.
The 26-bp primers NgoMIV KpnI NheI  NruI 5 and NgoMIV KpnI NheI 
NruI 3 were annealed and ligated in NruI-digested pDDB78 to give pDDB409.
Media and growth conditions. C. albicans was grown routinely at 30°C in YPD
(2% Bacto peptone, 2% dextrose, 1% yeast extract). For the selection of Ura,
His, or Trp transformants, synthetic medium without uridine, histidine, or
tryptophan was used (0.17% yeast nitrogen base without ammonium sulfate
[Q-BioGene], 0.5% ammonium sulfate, 2% dextrose, and supplemented with a
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TABLE 1. C. albicans and S. cerevisiae strains used in this study
Strain Parent/background Genotype
Reference
or source
DAY1 (BWP17) SC5314 ura3::imm434/ura3::imm434 his1::hisG/his1::hisG arg4::hisG/arg4::hisG 78
DAY25 BWP17 ura3::imm434/ura3::imm434 HIS1::his1::hisG/his1::hisG arg4::hisG/arg4::hisG
rim101::ARG4/rim101::URA3
15
DAY185 DAY286 ura3::imm434/ura3::imm434 HIS1::his1::hisG/his1::hisG
ARG4::URA3::arg4::hisG/arg4::hisG
15
DAY286 BWP17 ura3::imm434/ura3::imm434 his1::hisG/his1::hisG ARG4::URA3::arg4::hisG/arg4::hisG 78
DAY414 (L40) S. cerevisiae MAT his3200 trp1-901 leu2-3,-112 ade2 LYS2::(lexAop)4-HIS3 URA3::(lexAop)8-lacZ
GAL4
74
DAY415 (VIC1)a BWP17 ura3::imm434/ura3::imm434 his1::hisG/his1::hisG arg4::hisG/arg4::hisG
mds3::ARG4/MDS3
18
DAY439 (VIC25) BWP17 ura3::imm434/ura3::imm434 HIS1::his1::hisG/his1::hisG arg4::hisG/arg4::hisG
mds3::Tn7::URA3/mds3::Tn7::UAU1
18
DAY938 BWP17 ura3::imm434/ura3::imm434 his1::hisG/his1::hisG arg4::hisG/arg4::hisG
mds3::ARG4/mds3::URA3-dpl200
This study
DAY956 DAY938 ura3::imm434/ura3::imm434 his1::hisG/his1::hisG arg4::hisG/arg4::hisG
mds3::ARG4/mds3::dpl200
This study
DAY971 (CM02) RM1000 ura3::imm434/ura3::imm434 his1::hisG/his1::hisG sit4::HIS1/sit4::URA3 46
DAY972 (CM20) RM1000 ura3::imm434/ura3::imm434 his1::hisG/his1::hisG sit4::HIS1/sit4::dpl200 46
DAY973 (CM22) RM1000 ura3::imm434/ura3::imm434 his1::hisG/his1::hisG sit4::HIS1/sit4::dpl200 pVEC1::SIT4 46
DAY1109 (CDH107) CAI4 ura3::imm434/ura3::imm434 ras1::hisG-URA3-hisG/ras1::hisG 45
DAY1118 DAY938 ura3::imm434/ura3::imm434 HIS1::his1::hisG/his1::hisG arg4::hisG/arg4::hisG
mds3::ARG4/mds3::URA3-dpl200
This study
DAY1119 DAY938 ura3::imm434/ura3::imm434 HIS1::MDS3::his1::hisG/his1::hisG arg4::hisG/arg4::hisG
mds3::ARG4/mds3::URA3-dpl200
This study
DAY1120 DAY938 ura3::imm434/ura3::imm434 his1::hisG/his1::hisG arg4::hisG/arg4::hisG mds3::
ARG4/mds3::URA3-dpl200 TOR1-1/TOR1
This study
DAY1121 DAY185 ura3::imm434/ura3::imm434 HIS1::his1::hisG/his1::hisG
ARG4::URA3::arg4::hisG/arg4::hisG TOR1-1/TOR1
This study
DAY1122 DAY938 ura3::imm434/ura3::imm434 his1::hisG/his1::hisG arg4::hisG/arg4::hisG
mds3::ARG4/mds3::URA3-dpl200 TOR1/tor1::HIS1
This study
DAY1123 DAY286 ura3::imm434/ura3::imm434 his1::hisG/his1::hisG ARG4::URA3::arg4::hisG/arg4::hisG
TOR1/tor1::HIS1
This study
DAY1124 DAY1122 ura3::imm434/ura3::imm434 his1::hisG/his1::hisG arg4::hisG/arg4::hisG
mds3::ARG4/mds3::URA3-dpl200 TOR1-1/tor1::HIS1
This study
DAY1125 DAY1123 ura3::imm434/ura3::imm434 his1::hisG/his1::hisG ARG4::URA3::arg4::hisG/arg4::hisG
TOR1-1/tor1::HIS1
This study
DAY1208 (MWY64) SK1 MATa/MAT his3/his3 leu2::hisG/leu2::hisG trp1::hisG/trp1::hisG lys2/lys2 ura3/ura3
ho::LYS2/ho::LYS2
54
DAY1209 (CMY164) SK1 MATa/MAT mds3::URA3/mds3::URA3 his3/his3 leu2::hisG/leu2::hisG
trp1::hisG/trp1::hisG lys2/lys2 ura3/ura3 ho::LYS2/ho::LYS2
54
DAY1210 (CMY165) SK1 MATa/MAT pmd1::LEU2/pmd1::LEU2 his3/his3 leu2::hisG/leu2::hisG
trp1::hisG/trp1::hisG lys2/lys2 ura3/ura3 ho::LYS2/ho::LYS2
54
DAY1211 (CMY166) SK1 MATa/MAT mds3::URA3/mds3::URA3 pmd1::LEU2/pmd1::LEU2 his3/his3
leu2::hisG/leu2::hisG trp1::hisG/trp1::hisG lys2/lys2 ura3/ura3 ho::LYS2/ho::LYS2
54
DAY1223 (YAG171) CAI4 ura3::imm434/ura3::imm434 rbp1::MX3/rbp1::CaURA3MX3R 13
DAY1230 DAY1223 ura3::imm434/ura3::imm434 rbp1::MX3/rbp1::MX3 This study
DAY1231 DAY972 ura3::imm434/ura3::imm434 his1::hisG/his1::hisG sit4::HIS1/sit4::dpl200
MDS3/mds3::URA3-dpl200
This study
DAY1232 DAY1231 ura3::imm434/ura3::imm434 his1::hisG/his1::hisG sit4::HIS1/sit4::dpl200
MDS3/mds3::dpl200
This study
DAY1233 DAY1232 ura3::imm434/ura3::imm434 his1::hisG/his1::hisG sit4::HIS1/sit4::dpl200
mds3::URA3-dpl200/mds3::dpl200
This study
DAY1234 DAY1 ura3::imm434/ura3::imm434 his1::hisG/his1::hisG arg4::hisG/arg4::hisG SIT4/SIT4-
Myc-URA3
This study
DAY1235 DAY1234 ura3::imm434/ura3::imm434 HIS1::MDS3::his1::hisG/his1::hisG arg4::hisG/arg4::hisG
SIT4/SIT4-Myc-URA3
This study
DAY1236 DAY1234 ura3::imm434/ura3::imm434 HIS1::MDS3-HA::his1::hisG/his1::hisG
arg4::hisG/arg4::hisG SIT4/SIT4-Myc-URA3
This study
DAY1237 DAY1230 ura3::imm434/ura3::imm434 rbp1::MX3/rbp1::MX3 MDS3/mds3::URA3dpl200 This study
DAY1238 DAY1237 ura3::imm434/ura3::imm434 rbp1::MX3/rbp1::MX3 MDS3/mds3::dpl200 This study
DAY1239 DAY1238 ura3::imm434/ura3::imm434 rbp1::MX3/rbp1::MX3 mds3::dpl200/mds3::URA3dpl200 This study
DAY1255 DAY1120 ura3::imm434/ura3::imm434 HIS1::his1::hisG/his1::hisG arg4::hisG/arg4::hisG mds3::
ARG4/mds3::URA3-dpl200 TOR1-1/TOR1
This study
DAY1321 DAY972 ura3::imm434/ura3::imm434 his1::hisG/his1::hisG sit4::HIS1/sit4::dpl200 TOR1-1/TOR1 This study
a Parent of VIC3 (mds3::ARG4/mds3::URA3). VIC1 was not described by Davis et al. (6).
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dropout mix containing amino and nucleic acids except those necessary for the
selection [1]). Media were buffered at the indicated pH using 150 mM HEPES.
The assays for filamentation in the presence of rapamycin were performed in
M199 medium (Gibco BRL) buffered at pH 8 and SLAD (0.17% yeast nitrogen
base without ammonium sulfate [Q-BioGene], 50 	M ammonium sulfate, 2%
dextrose). Filamentation assays were conducted at 37°C except as indicated.
Rapamycin (LC Laboratories) was added to the media at the indicated concen-
trations from a stock solution in 90% ethanol–10% Tween 20. For liquid assays
of filamentation in the presence of rapamycin, strains were pregrown in liquid
YPD at 30°C, pelleted, resuspended in an equal volume of phosphate-buffered
saline (PBS), and diluted 1:100 in M199, pH 8, supplemented with rapamycin or
solvent alone. Samples were incubated for 6 h. To determine the percentage of
hypha-producing cells, samples were gently sonicated and quantified under the
microscope. The values reported represent the averages from at least two inde-
pendent experiments, in which every strain was tested at least in duplicate. For
filamentation in serum, strains were pregrown in liquid YPD at 30°C, diluted
1:100 in liquid YPD supplemented with 10% fetal bovine serum (Gibco), and
incubated at 37°C for 5.5 h. For growth assays in the presence of rapamycin,
strains were pregrown in liquid YPD at 30°C, diluted in PBS to an optical density
at 600 nm (OD600) of 1.6, and then serially diluted 5-fold in PBS, spotted on
YPD or Spider medium (1% mannitol, 1% nutrient broth, 0.2% K2HPO4, pH
7.2, before being autoclaved [47]), supplemented with rapamycin or solvent
alone, and incubated at 30°C for 2 or 3 days. All media except that for the
selection of Ura transformants were supplemented with 80 	g/ml uridine. For
solid media, 2% Bacto agar was added, except for Spider medium, which used
1.35% Bacto agar.
Microarray analysis. Strains were pregrown in YPD at 30°C, pelleted, washed
with M199 (pH 4 or pH 8) medium, diluted 40-fold in prewarmed M199 (pH 4
TABLE 2. Primers used in this study
Name Sequencea (5 to 3) Reference
MDS3 5DR TCTTAAGGCACAAGTTATTGGCTTGACGTAGAAGTTTGCAAAGATTTTCACAATATC
ATGTTTCCCAGTCACGACGTT
18
MDS3 3DR ACCAATATAACGTGAATATACACCCCTATATTATTATCTTTTAATCCTGTTAACAATC
CGTGGAATTGTGAGCGGATA
18
MDS3null 5-detect GTGTCCCAATTTTGTCTAGC This study
MDS3null 3-detect TGCGGAAGAACTGTAAACCC This study
TOR1 5DR AGTAGATAATACTTCTAACTTTGATAGTAACATTAACGAAGAAAAACAAATCATTA
ATCATTTCCCAGTCACGACGTT
This study
TOR1 3DR TATTTCCCTTTATAAAATAGTTACACATACCATACTTAACGACACATGACGATACTC
AACGTGGAATTGTGAGCGGATA
This study
TOR1 5detect-2 TCTCTTAGTTGTTGAGTGGC This study
TOR1 3detect AAATTTCCTTCCAAACCTGC This study
TOR1 A-C GTTTTATGGCACGAACAATGGCACGATGCTTTGGAAGATGCTCGCAGGTTTTTCTTT
GGTGAACACAACACAGAAAAGATG
This study
TOR1 A-C Rev CATCTTTTCTGTGTTGTGTTCACCAAAGAAAAACCTGCGAGCATCTTCCAAAGCATC
GTGCCATTGTTCGTGCCATAAAAC
This study
JOHE6247 GGCAAGGTGTTTCTTGAAGC 13
JOHE6248 TACTTCTTGATTCGCGATAGC 13
DDB78 PmeIxNruI 5 ATAATCAAAATGAGTCAATTCTCACAACCGCTCGGTTTAAACCGACACGTTTCAACG
AAATGGCCTCCCCTACCA
This study
DDB78 PmeIxNruI 3 TGGTAGGGGAGGCCATTTCGTTGAAACGTGTCGGTTTAAACCGAGCGGTTGTGAGA
ATTGACTCATTTTGATTAT
This study
MDS3 5comp new AAGCTCGGAATTAACCCTCACTAAAGGGAACAAAAGCTGGTGGTCTTTAATTGGGC
GGAC
This study
MDS3 3comp new-2 ACGACGGCCAGTGAATTGTAATACGACTCACTATAGGGCGGTTCTCGATTAGTCCA
TTGACCTGCC
This study
MDS3 5-2comp new GATGGAGAGATGGGGACAGC This study
MDS3 3-2comp new-2 TTTGTCATGTTCACCCGACG This study
TOR1 probe 5 ATGAAATAGTGAGTCGCTCC This study
TOR1 probe 5-2 CTTTTGTTGCAAATGGCACC This study
TOR1 probe 3 CTACCAAGCATAATGGGGTC This study
RPS26A 5 CAAGAAAGGTAGAGGTCACG This study
RPS26A 3 TTTAGCAGCATCTTGTGGAG This study
CDC19 5 a CTTCAATGTTGAAACTGTTCC This study
CDC19 3 b AACAGTGTTAGAGTGACCAG This study
GAP2 5 TTATTGTACAGTTATGTCCC This study
GAP2 3 CCAGCGAAAGCAAAGGCAGC This study
TEF1-5 ATAGTCATAATCAATCATGGGT 16
TEF1-3 CTTACATAATATTCAACTAGC 16
Sit4 MYC N-ter 5 GATGGTGACTTATCAGTCAAGAACAATGCCAACAAACAACAAAGAAGTGATTATTT
TTTGCGGATCCCCGGGTTAATTAA
This study
Sit4 MYC URA3 N-ter 3 GCATCATTAAGGGATTTGAAAAAAAAAGATATAAATATAAAAATCATTCATCATTC
GTTATCTAGAAGGACCACCTTTGATTG
This study
5 Myc detect GAACAAAAATTAATTTCTGAAGAAGATTTA This study
Sit4 3 detect TGGTTTGTATGTGTAAGTCC This study
NgoMIV KpnI NheI x NruI 5 TAGCCGGCTGGGTACCCGGCTAGCCA This study
NgoMIV KpnI NheI x NruI 3 TGGCTAGCCGGGTACCCAGCCGGCTA This study
MDS3-HA-56 5 AGCTTCGAAAATTCATGCAGATAGTGTCGCAATGTCTTTGTACCCATACGATGTTCC
TGAC
This study
MDS3-HA-56 3 AAGCATTTCGCAGATTATTACTTGTAACCGATTTCTTTTTGTAATCTGGAACGTCAT
ATGG
This study
a The sequences underlined indicate the restriction site created. Sequences in boldface and underlined indicate point mutations.
3698 ZACCHI ET AL. MOL. CELL. BIOL.
 o
n
 July 26, 2016 by University of Queensland Library
http://m
cb.asm
.org/
D
ow
nloaded from
 
or pH 8), and incubated for 4 h at 37°C with agitation. Procedures for RNA
extraction, microarray construction, and analysis have been described previously
(6). Corrected P values for the gene ontology (GO) categories were obtained
using the GO term-finder algorithms available through the Candida Genome
Database website (www.candidagenome.org) in February 2009.
Northern blot analysis. Cells were grown overnight in YPD at 30°C. The
following day, cells were washed with M199 medium at either pH 4 or 8 and
diluted 40-fold into fresh M199 (pH 4 or 8) medium containing solvent or 5 nM
rapamycin and incubated for 4 h at 37°C with agitation. For Spider medium
experiments, cells were diluted 1:40 in Spider medium containing solvent or 5
nM rapamycin and incubated for 4 h at 37°C with agitation. For YPD medium
experiments, cells were grown as described previously (4). Briefly, YPD over-
night cultures were inoculated into YPD at an OD of 
0.1. Cells were grown 5 h
at 30°C, followed by 1 h at 30°C with solvent or 20 nM rapamycin. Cells then were
harvested and frozen in a dry ice-ethanol bath. RNA extraction and Northern
blot procedures were previously described (6), except that the PCR products for
the probes were purified with a PCR purification kit (Qiagen). RNA concentra-
tion was measured using a NanoDrop spectrophotometer ND-1000. Probes for
ECE1 and HWP1 were described previously (18).
Statistical analysis. Statistical analysis for data shown in Table 5 was per-
formed using the software SAS 9.13 (SAS Institute Inc.). We used repeated
analyses of covariance (ANCOVA) (assuming different variances for each strain)
and included the day of the experiment as the covariate. We tested for strain-
treatment interaction and compared specific strain treatment effects after ad-
justing for multiple comparisons using Bonferroni’s correction (14 comparisons
were made; significant P values were 0.05/14, or 0.0036).
Microscopy. Pictures of colonies were taken using a Canon Powershot A560
digital camera on a Zeiss Opton microscope. Images of liquid cultures were
captured using a Zeiss Axio camera, Axiovision 4.6.3 software (Zeiss), and a
Zeiss AxioImager fluorescence microscope. All images were processed with
Adobe Photoshop 7.0 software.
Protein purification and Western blot analysis. Overnight cultures of C. albi-
cans were diluted 200-fold into M199 (pH 8) or YPD medium and grown for 4
to 5 h at 30°C. Cells were pelleted and resuspended in ice-cold radioimmuno-
precipitation assay (RIPA) buffer (50 mM Tris, pH 8, 150 mM NaCl, 1% NP-40,
3 mM EDTA, 0.5% deoxycholate, 0.1% sodium dodecyl sulfate [SDS]) contain-
ing 1 	g/ml leupeptin, 2 	g/ml aprotinin, 1 	g/ml pepstatin, 0.1 mM phenyl-
methylsulfonyl fluoride, and 10 mM dithiothreitol and lysed by vortexing with
acid-washed glass beads for 1 h at 4°C. Cell lysates were pelleted and superna-
tants stored at 80°C. For Western blot assays of the input, 
1.25 mg of total
protein was resuspended in 2 SDS gel-loading buffer (100 mM Tris-Cl, pH 6.8;
200 mM dithiothreitol; 4% SDS; 0.1% bromophenol blue; 20% glycerol), boiled
at 95 to 100°C for 3 min, and run in an 8% SDS-PAGE gel. Proteins were
transferred to nitrocellulose and blocked in 6% nonfat milk in TBS-T (50 mM
Tris, pH 7.6, 150 mM NaCl, 0.1% Tween 20). Blots were incubated with anti-HA
(F-7 probe; Santa Cruz) or anti-Myc (Invitrogen) at 1:1,000 or 1:5,000 dilution,
respectively, in 6% nonfat milk TBS-T, washed in TBS-T, and incubated with
anti-mouse antibody–horseradish peroxidase (GE Healthcare) at 1:5,000 in 6%
nonfat milk in TBS-T. Blots were washed in TBS-T, incubated with ECL reagent
(GE Healthcare), and exposed to film.
Coimmunoprecipitations. Mds3-HA was immunoprecipitated as follows. To-
tal protein (
18 mg) was incubated overnight at 4°C with 20 	l of slurry anti-HA
agarose beads (Sigma-Aldrich). Beads were washed four times with Tris-buffered
saline (25 mM Tris, 0.15 M NaCl, pH 7.2, 0.05% Tween). Protein was eluted
from the beads by resuspension in 50 	l 2 SDS gel loading buffer and boiling
for 5 min. The products of two immunoprecipitations were combined, separated
by SDS-PAGE, and analyzed by Western blotting.
RESULTS
Mds3 affects TOR-dependent gene expression. Mds3 acts in
parallel to the Rim101 pathway to promote the yeast-to-hypha
morphogenetic switch in response to neutral-alkaline pH
(18). To gain insights into how Mds3 contributes to pH
responses, we determined the transcriptional profiles of
wild-type, rim101/, and mds3/ strains grown at pH 8 and
4 (see Table S1 in the supplemental material). The microarray
experiments for all three strains were performed concomi-
tantly, but the results for the wild-type and rim101/ strains,
including the microarray methodology and validation, have
been reported previously (6).
Since Mds3 and Rim101 are required for growth and mor-
phogenesis at alkaline pH, we expected that most transcrip-
tional differences observed between the mutant strains and the
wild type would occur at pH 8. Indeed, 
80% (287) and 
95%
(180) of all differentially expressed ORFs in the mds3/ and
rim101/ mutants, respectively, occurred at pH 8 (Table 3)
(6). Further, because the mds3/ and rim101/ mutants are
defective for filamentation at alkaline pH, we expected to find
common changes in the expression of hypha-associated genes.
In fact, the expression of genes associated with cell wall/fila-
mentation were decreased in the mds3/ and rim101/ mu-
tants relative to that of the wild-type strain (Table 4) (6). Thus,
mds3/ and rim101/ mutants share similar transcriptional
defects, as predicted based on their similar phenotypes at al-
kaline pH.
However, as Mds3 and Rim101 act in parallel, we also ex-
pected to find differences between the transcriptional profiles
of these mutants relative to that of the wild-type strain. In-
deed, several fundamental differences were observed. First, the
mds3/ mutant affected the expression of twice as many
genes as did the rim101/mutant (363 versus 187 total ORFs,
respectively) (Table 3). Approximately 60% (229) of the genes
affected by the mds3/ mutant were not pH regulated in
wild-type cells, compared to 
38% (72) of the genes in the
rim101/ mutant (Fig. 1). Second, the mds3/ mutant af-
fected the expression of more genes at pH 4 than the
rim101/ mutant (76 versus 7 genes, respectively) (Table 3).
Third, in the rim101/ mutant, 
70% of the differentially
expressed genes showed reduced expression, suggesting that
Rim101 primarily functions as a positive regulator (Table 3).
However, in the mds3/ mutant, the differentially expressed
genes showed increased and reduced expression at an 
50:50
ratio, demonstrating that Mds3 functions as both a positive and
negative regulator (Table 3). Overall, these results suggest that
TABLE 3. Results of the transcriptional profiling of the wild-type, mds3/, and rim101/ C. albicans strains
Condition
No. of ORFs with
2-fold difference
No. of ORFs expressed more
in the mutant
No. of ORFs expressed less
in the mutant
mds3/ rim101/a Mds3/ rim101/a mds3/ rim101/a
WT pH 8 versus mutant pH 8 337 186 146 55 191 131
WT pH 4 versus mutant pH 4 76 7 37 1 39 6
ORFs 2-fold difference at pH 8 and 4 50 6
Total 363 187
a Data are from reference 6.
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Mds3 has broader effects on gene expression than Rim101
and that Mds3 has roles in addition to adaptation to envi-
ronmental pH.
To identify potential biological functions for Mds3, we ana-
lyzed the Mds3-dependent genes by gene ontology (GO). Of
the genes upregulated in the mds3/ mutant compared to the
wild-type strain, the GO categories of glycolysis and translation
were significantly overrepresented (P  1.1E04 and P 
5.3E15, respectively) (Table 4; also see Table S1 in the sup-
plemental material). In wild-type cells, most of the ORFs in
translation were expressed preferentially at pH 8 compared to
pH 4 (6). This suggests that the loss of Mds3 enhances these
gene expression changes observed in wild-type cells at alkaline
pH. Of the genes downregulated in the mds3/ mutant com-
pared to the wild-type strain, the GO categories of amino acid
transport and vacuolar protein catabolic activity (P 4.7E04
and P  1.6E03, respectively) were significantly overrepre-
sented (Table 4). Further, the categories of amine transport,
lytic vacuole, glycolysis, and translation also were overrepre-
sented when this analysis was done in the mds3/ mutant
exclusively for genes that are pH independent (data not
shown). These results show that Mds3 affects a variety of dis-
tinct processes, including growth and starvation responses, and
supports the idea that Mds3 has functions in pH-independent
processes.
To corroborate the microarray results, we analyzed the ex-
pression of several MDS3-dependent ORFs by Northern blot-
ting (Fig. 2A). In M199 pH 8 medium, the glycolysis gene
CDC19 and the translation genes RPS26A and TEF1 were ex-
pressed 
2- to 4-fold more in the mds3/ mutant than the
wild-type or the complemented mds3/ MDS3 strains (Fig.
2A, lanes 6 to 8). The increased expression of CDC19, RPS26A,
TABLE 4. GO categories of differentially expressed ORFs in the mds3/ and rim101/ mutants
compared to those of wild-type C. albicans
GO category
No. of ORFs
Expressed more at pH 8 Expressed less at pH 8 Expressed more at pH 4 Expressed less at pH 4
mds3/ rim101/ mds3/ rim101/ mds3/ rim101/ mds3/ rim101/
Amino acid biosynthesis 11 1 8 4 6 0 3 3
Carbohydrate metabolism 15 3 8 3 8 0 0 0
Glycolysis 6 0 0 0 5 0 0 0
Translation 50 0 1 1 0 0 0 0
Initiation/elongation 6 0 0 0 0 0 0 0
rRNA/tRNA processing 5 0 0 0 0 0 0 0
Ribosome 37 0 1 0 0 0 0 0
Mitochondrial 2 0 0 1 0 0 0 0
Protein synthesis/folding 15 2 1 2 2 0 0 0
Protein degradation/autophagy 2 0 11 0 0 0 1 1
Vacuolar protein catabolic activity 0 0 5 0 0 0 0 1
Amino acid degradation/proteosome 2 0 3 0 0 0 1 0
Others 0 0 3 0 0 0 0 0
Lipid metabolism 4 1 10 4 1 0 0 0
Permeases/transport 9 9 33 25 2 0 13 0
Amino acid transport 0 2 12 5 0 0 4 0
Hexose transport 4 0 4 1 1 0 1 0
Other transport 5 7 17 19 1 0 8 0
DNA replication/transcription 7 1 2 0 1 0 2 0
Transcription factor/signal transduction 2 2 13 4 3 0 5 0
Electron transport 2 0 3 0 1 0 0 0
Cell wall/filamentation 4 2 22 17 1 1 3 2
Other 10 7 19 23 4 0 4 0
Unknown/novel 15 27 60 48 8 0 8 0
Total ORFs 146 55 191 131 37 1 39 6
FIG. 1. VENN diagram of wild-type and Mds3- and Rim101-de-
pendent genes. Differentially expressed genes in the mds3/ or
rim101/ mutant versus expression in the wild-type strain were sep-
arated into pH-dependent and pH-independent groups depending on
whether these ORFs were differentially expressed in wild-type cells in
response to pH. Genes that were differentially regulated in the
mds3/ or rim101/ mutant versus that in the wild-type strain at
both pH 8 and 4 were included only once in this analysis. Numbers in
parentheses represent the percentages of ORFs that are pH indepen-
dent.
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and TEF1 in the mds3/ mutant also was observed at pH 4
(Fig. 2A, lanes 1 to 3), suggesting that Mds3 governs the
expression of these genes in a pH-independent manner. GAP2,
an amino acid transport gene, was reduced 2-fold in the
mds3/ mutant compared to the wild-type or the mds3/
MDS3-complemented strain at both pH 4 and 8 (Fig. 2A,
compare lanes 2 and 7 to lanes 1, 3, 6, and 8). These results
establish the veracity of the microarray data and support the
idea that Mds3 has pH-independent functions.
The GO categories affected by the mds3/ mutant reflect
processes that are transcriptionally regulated by the TOR
pathway. During conditions of active growth, TOR positively
regulates the expression of genes involved in ribosomal bio-
genesis, translation initiation and elongation, rRNA and tRNA
synthesis, and glycolysis (79), and it negatively regulates the
expression of genes involved in protein degradation and nitro-
gen catabolite repression (NCR) (4, 8, 35, 68). During starva-
tion conditions, TOR is inactive and genes involved in trans-
lation and glycolysis are repressed, while genes involved in
amino acid transport and vacuolar degradation are induced (4,
8, 35, 68). Since the mds3/ mutant shows gene expression
differences that reflect TOR activation, we hypothesized that
Mds3 functions as a negative regulator of TOR.
To address the idea that Mds3 is a negative regulator of TOR,
we predicted that rapamycin, a TOR inhibitor (36), would rescue
the transcriptional defects associated with the mds3/ mu-
tant. Indeed, 5 nM rapamycin reduced the expression of
CDC19, RPS26A, and TEF1 and restored the expression of
GAP2 in mds3/ mutant cells compared to that with solvent
alone (Fig. 2A, compare lanes 6 to 8 and 11 to 13). Rapamycin
did not appear to affect the expression of RPS26A, TEF1, and
GAP2 in the wild-type or mds3/ MDS3 complemented
FIG. 2. Microarray validation by Northern blot analysis. Overnight YPD cultures of the wild-type (DAY185), mds3/ (DAY1118), mds3/
MDS3 (DAY1119), sit4/ (DAY972), sit4/ mds3/ (DAY1233), and mds3/ rbp1/ (DAY1239) strains were diluted in prewarmed
M199 pH 8 (A), Spider medium (B), or YPD (C) with or without rapamycin. Ethidium bromide staining was used as a loading control, because
commonly used loading controls (TEF1, ACT1, or TDH3) varied in expression due to the mutations, the growth conditions, and/or the addition
of rapamycin. MDS3, SIT4, and RBP1 genotypes are noted above the samples: wild-type (), deletion (), or complemented (p).
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strains; however, the expression of CDC19 was increased 
2-
fold compared to that in solvent alone. Regardless, in the
presence of rapamycin the expression of CDC19, RPS26A,
TEF1, and GAP2 was quantitatively similar in wild-type,
mds3/, and mds3/ MDS3 cells. These results demon-
strate that rapamycin restores the transcriptional defects due
to the loss of Mds3 and corroborates the idea that Mds3 acts as
a negative regulator of TOR.
In nutrient-poor Spider medium, we observed similar transcrip-
tional results (Fig. 2B). The expression of CDC19, RPS26A, and
TEF1 was increased in the mds3/ mutant compared to that
of the wild type (Fig. 2B, compare lanes 1 and 2). Further, the
addition of rapamycin reduced CDC19, RPS26A, and TEF1
expression in the mds3/ mutant-, wild-type-, and mds3/
MDS3-complemented strains. We noted that in Spider me-
dium this rapamycin-dependent restoration of gene expression
in the mds3/mutant was less than that observed in M199 pH
8 medium. We also found that in Spider medium, GAP2 was
expressed poorly in wild-type cells and expressed at greater
levels in the absence of MDS3. The addition of rapamycin
increased GAP2 expression in all strains tested (Fig. 2B, com-
pare lanes 1 to 5 with 6 to 10). These results support the idea
that Mds3 acts in the TOR pathway and suggests that, not
surprisingly, growth medium differences cause distinct effects.
Rapamycin rescues the mds3/ mutant filamentation de-
fect. The TOR pathway regulates fungal morphogenesis (14),
and rapamycin triggers the expression of hypha-associated genes
in C. albicans (4). Since Mds3 also regulates morphogenesis
and is required for the expression of hypha-associated genes
(18), we asked if rapamycin also rescues the expression of these
genes in the mds3/ mutant (Fig. 3A). Wild-type, mds3/,
and mds3/ MDS3 cells were incubated in M199 pH 8
medium at 37°C, which promotes hypha formation, with and
without 5 nM rapamycin and analyzed the expression of the
hypha-associated genes HWP1 and ECE1 (Fig. 3A). While the
mds3/ mutant showed little HWP1 and ECE1 expression,
the addition of rapamycin completely restored this expression
(Fig. 3A, compare lanes 2 and 5). We noted that rapamycin
also led to the increased expression of HWP1 and ECE1 in
both wild-type and mds3/ MDS3 strains compared to that
in solvent alone. Thus, rapamycin promotes the expression of
hypha-associated genes and rescues the mds3/ mutant de-
fects in HWP1 and ECE1 expression.
Since rapamycin rescued the transcriptional defects associ-
ated with the loss of Mds3, we asked if rapamycin also could
rescue the hyphal formation defect of the mds3/ mutant. In
liquid M199 pH 8 medium at 37°C, 90% of wild-type cells
germinated to form hyphae; 5% of mds3/ mutant cells
germinated to form hyphae (Table 5 and Fig. 3B). However,
the addition of 5 nM rapamycin partially restored hyphal for-
mation in the mds3/ mutant to 45% (P  0.0001 compared
to mds3/ in solvent) (Fig. 3B and Table 5). Rapamycin also
promoted hyphal formation in wild-type cells compared to
formation in the solvent control (P  0.001) (Table 5), and we
noted that the hyphae formed in the wild-type, mds3/, and
mds3/ MDS3 strains in the presence of rapamycin ap-
peared less branched than in solvent alone. Similar results
were observed in liquid SLAD medium, a nutrient-poor
medium, indicating that the effect of rapamycin is not spe-
FIG. 3. Rapamycin rescues mds3/ hypha-associated phenotypes.
(A) Northern blots of hypha-associated genes performed on the wild-
type (DAY185), mds3/ (DAY1118), mds3/MDS3 (DAY1119),
and sit4/ (DAY972) strains grown for 4 h in M199, pH 8, supple-
mented with solvent or 5 nM rapamycin. MDS3 and SIT4 genotypes
are noted above the samples: wild-type (), deletion (), or comple-
mented (p). EtBr, ethidium bromide. (B) Overnight YPD cultures of
the wild-type (DAY185), mds3/ (DAY1118), mds3/ MDS3
(DAY1119), sit4/ (DAY972), sit4/ SIT4 (DAY973), mds3/
sit4/ (DAY1233), rim101/ (DAY25), and ras1/ (DAY1109)
strains were washed in PBS and diluted 1:100 in M199 liquid medium
(pH 8) with or without 5 nM rapamycin. Cells were visualized under
the microscope (40 magnification) after 6 h of incubation at 30
or 37°C.
TABLE 5. Hyphal formation in M199 pH 8 in the presence and
absence of 5 nM rapamycin
Strain Genotype
% of hyphae  SEM
Solvent Rapamycin
DAY185 MDS3/MDS3 TOR1/TOR1 88.5  2.0 98.3  2.0
DAY1121 MDS3/MDS3 TOR1-1/TOR1 85.0  2.2 89.6  2.2
DAY1123 MDS3/MDS3 TOR1/ 94.3  0.7 98.5  0.7
DAY1125 MDS3/MDS3 TOR1-1/ 90.6  1.6 93.3  1.6
DAY1118 mds3/ TOR1/TOR1 2.9  3.2 44.5  3.2
DAY1120 mds3/ TOR1-1/TOR1 5.0  3.2 23.4  3.2
DAY1122 mds3/ TOR1/ 5.1  1.8 37.3  1.8
DAY1124 mds3/ TOR1-1/ 0.9  0.3 0.8  0.3
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cific to M199 medium (Fig. 4A). These results demonstrate
that rapamycin rescues the morphogenetic defect of the
mds3/ mutant.
We found that the effect of rapamycin on hyphal formation
was not due to translational inhibition, because cycloheximide
did not rescue the filamentation defect of the mds3/
mutant (Fig. 4B). Further, rapamycin is not a constitutive
inducer of hyphal formation, because rapamycin did not
rescue the mds3/ hyphal formation defect in M199 pH 8
medium at 30°C (Fig. 3B). These results demonstrate that
rapamycin is not a constitutive inducer of hyphal formation
and further support a link between Mds3 and TOR.
To determine if the effect of rapamycin was actually depen-
dent on TOR, we introduced the rapamycin-resistant TOR1-1
allele into the wild-type and mds3/ strains and determined if
rapamycin still promoted hyphal formation (7, 13). As ex-
pected, strains carrying a TOR1-1 allele were resistant to rapa-
mycin (Fig. 5A). In the absence of rapamycin, the TOR1-1
allele did not affect hyphal formation in either the MDS3/
MDS3 or mds3/ background (Fig. 5B and Table 5). How-
ever, in the presence of rapamycin, the TOR1-1 allele pre-
vented the rapamycin-induced hyphal formation observed in
MDS3/MDS3 cells (Table 5), and the hypha formed showed a
branching pattern similar to that of the wild-type strain without
rapamycin (Fig. 5B). Thus, in the MDS3/MDS3 background
rapamycin-mediated phenotypes are TOR dependent. In the
presence of rapamycin, the TOR1-1 allele reduced the rapa-
mycin-induced hyphal formation observed in mds3/ cells by

50% (Table 5). We hypothesized that the semiresponsive
effect of rapamycin in the mds3/ TOR1-1/TOR1 mutant was
an attribute of the remaining wild-type TOR1 allele. To ad-
dress this possibility, we constructed TOR1-1/ strains in the
MDS3/MDS3 and mds3/ backgrounds. The deletion of one
copy of TOR1 in either background had no significant effect on
hyphal formation (Fig. 5B and Table 5), demonstrating that
TOR1 is not haploinsufficient. While the MDS3/MDS3 TOR1-
1/ strain filamented similarly to the MDS3/MDS3 TOR1-1/
TOR1 strain in the presence or absence of rapamycin, the
mds3/ TOR1-1/ strain failed to filament in the presence or
absence of rapamycin (Fig. 5B and Table 5). The mds3/
TOR1-1/ mutant did form hyphae in serum, an MDS3-inde-
pendent inducer of hyphal formation (data not shown and
reference 18), demonstrating that the mds3/ TOR1-1/
strain did not have an absolute block in hyphal formation.
These results demonstrate that rapamycin rescues mds3/
phenotypes through TOR.
We noted that in the absence of a wild-type copy of TOR1,
the TOR1-1 allele conferred growth defects in both the wild-
type and mds3/ backgrounds (Fig. 5A and 6), demonstrating
that the TOR1-1 allele is not completely functional. Thus, we
considered that this growth defect could influence our hyphal
formation data. To address this, we constructed an mds3/
rbp1/ double mutant that did not have a growth defect (Fig.
5A). Rapamycin inhibits the TOR kinase as a complex with
Rbp1 (FKBP12 in mammals), and rbp1/ mutants are rapa-
mycin resistant (Fig. 5A and reference 13). While rbp1/
mutants did not have a defect in hyphal formation, the loss of
Rbp1 in the mds3/ background completely blocked the abil-
ity of rapamycin to rescue the mds3/ hyphal formation de-
fects (Fig. 5B and Table 6). The loss of Rbp1 also prevented
the transcriptional effects of rapamycin in the mds3/ mutant
(Fig. 2A, lanes 16 to 18, and C, lanes 11 and 12). In total, these
results clearly demonstrate that the transcriptional effects of
the mds3/ mutant have biological consequences that are
associated with the inappropriate activation of the TOR
pathway.
Mds3 and the TOR effector Sit4 act similarly. One down-
stream effector of the TOR pathway is the type 2A-like phos-
phatase Sit4 (22, 23, 66). Sit4 promotes starvation responses
and is inhibited by TOR-dependent phosphorylation during
periods of active growth (21, 40). Thus, in the absence of Sit4,
TOR-dependent starvation responses are defective. Since the
mds3/ mutant also is defective for TOR-dependent starva-
tion responses and promotes TOR activation (Table 4 and Fig.
2), we predicted that a sit4/ mutant has transcriptional de-
fects similar to those of the mds3/ mutant. Indeed, in the
FIG. 4. Rapamycin rescues mds3/ filamentation defects in nutri-
ent-poor medium but cycloheximide does not. (A) Wild-type (DAY185),
mds3/ (DAY1118),mds3/MDS3 (DAY1119), sit4/ (DAY971),
sit4/ SIT4 (DAY973), and mds3/ sit4/ (DAY1233) cells were
grown for 6 h in SLAD liquid medium at 37°C with or without 10 nM
rapamycin. (B) Wild-type (DAY185) andmds3/ (DAY1118) cells were
grown for 6 h in M199 liquid medium (pH 8) at 37°C with or without 100
	M cycloheximide. Similar results were observed with 150 and 250 	M
cycloheximide, but higher concentrations inhibited the growth of all
strains tested.
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sit4/ mutant, CDC19, RPS26A, and TEF1 were expressed at
higher levels than those of the wild-type strain at both pH 4
and 8 (Fig. 2A, compare lanes 4 and 9 to lanes 1 and 6) and in
nutrient-poor Spider medium (Fig. 2B). We noted that at
pH 4, CDC19 expression in the sit4/ mutant was 
4-fold
higher than that in the mds3/ mutant. Further, in the
sit4/ mutant, GAP2 was not expressed at either pH 4 or 8,
although it was expressed more in Spider medium, similarly
to the mds3/ mutant. Thus, the loss of Sit4 has transcrip-
tional effects similar to those of the loss of Mds3.
The addition of rapamycin to sit4/ cells reduced the ex-
pression of CDC19, RPS26A, and TEF1 to approximately wild-
type levels in M199 pH 8 medium (Fig. 2A, compare lanes 9
and 14) but had a more modest effect on Spider medium (Fig.
2B). Rapamycin also promoted the expression of GAP2 in
sit4/ cells. However, in M199 pH 8 medium, GAP2 expres-
sion still was 
2-fold lower than that of wild-type cells, indi-
cating that Sit4 is required for the full induction of GAP2.
These results demonstrate that the loss of Sit4 promotes the
activation of the TOR pathway similarly to the loss of Mds3
and provides independent support for the idea that Mds3 acts
in the TOR pathway.
Sit4 also is required for hyphal formation in C. albicans (46)
(Fig. 3B). We found that sit4/ mutant cells expressed little
HWP1 and ECE1 in M199 pH 8 medium and that this defect
was partially rescued by the addition of rapamycin (Fig. 3A,
lanes 7 and 8). Similarly to the mds3/ mutant, rapamycin
rescued the sit4/ hyphal formation defect in M199 pH 8
(12.9%  0.1% in solvent versus 60.5%  2.6% in rapamycin)
and SLAD media (9.2%  1.0% in solvent versus 19.2% 
0.5% in rapamycin) (Fig. 3B and 4A), and this rescue was
prevented by the TOR1-1 rapamycin-resistant allele (Fig. 5A
and C). Importantly, rapamycin did not rescue the filamenta-
tion defects associated with the loss of Ras1 or Rim101, which
are not associated with the TOR pathway (Fig. 3B). In total,
these results suggest a functional association between Mds3
and Sit4.
FIG. 6. TOR1-1/ mds3/ mutant grows poorly. (A) Overnight
YPD cultures of the wild-type and the mds3/ backgrounds carrying
TOR1/TOR1 (DAY185 and DAY1118), TOR1/ (DAY1123 and
DAY1122), TOR1-1/TOR1 (DAY1121 and DAY1255), or TOR1-1/
alleles (DAY1125 and DAY1124) or the rbp1/ deletion (DAY1223
and DAY1239) were streaked onto YPD medium at 30°C for 2 days.
FIG. 5. Effect of rapamycin on filamentation is TOR dependent. (A) Wild-type (DAY185), TOR1-1/tor1 (DAY1125), rbp1/ (DAY1223),
mds3/ (DAY1118), mds3/ TOR1-1/tor1 (DAY1124), mds3/ rbp1/ (DAY1239), TOR1-1/TOR1 (DAY1121), sit4/ (DAY972), and
sit4/ TOR1-1/TOR1 (DAY1321) strains were grown overnight in YPD, and serial dilutions were spotted onto YPD with or without 15 nM
rapamycin. Overnight YPD cultures of the wild-type and the mds3/ backgrounds carrying TOR1/TOR1 (DAY185 and DAY1118), TOR1/
(DAY1123 and DAY1122), TOR1-1/TOR1 (DAY1121 and DAY1255), and TOR1-1/ alleles (DAY1125 and DAY1124) or the rbp1/ deletion
(DAY1223 and DAY1239) (B) and sit4/ TOR1/TOR1 (DAY972) and sit4/ TOR1-1/TOR1 (DAY1321) (C) were washed in PBS and diluted
1:100 in M199 liquid medium (pH 8) with or without 5 nM rapamycin.
TABLE 6. Hyphal formation in M199 pH 8 in the presence and
absence of 5 nM rapamycin
Strain Genotype
% of hyphae  SEM
Solvent Rapamycin
DAY185 MDS3/MDS3 RBP1/RBP1 75.6  2.9 84.9  4.0
DAY1233 MDS3/MDS3 rbp1/rbp1 91.4  1.1 91.1  1.7
DAY1118 mds3/ RBP1/RBP1 4.4  1.7 30.4  3.5
DAY1239 mds3/ rbp1/rbp1 3.0  0.9 3.5  1.0
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To determine if Mds3 and Sit4 act in the same pathway or
parallel pathways, we constructed an mds3/ sit4/ double
mutant. If Mds3 and Sit4 function in the same pathway, then
the mds3/ sit4/ double mutant should have phenotypes
similar to those of either single mutant; if Mds3 and Sit4
function in parallel pathways, then the mds3/ sit4/ double
mutant should have more severe phenotypes than either
single mutant. The mds3/ sit4/ double mutant ex-
pressed CDC19, RPS26A, TEF1, and GAP2 similarly to the
mds3/ and sit4/ single mutants in M199 pH 8 and Spider
media (Fig. 2A, compare lanes 7, 9, and 10). In M199 pH 4
medium, the mds3/ sit4/ double mutant behaved simi-
larly to the sit4/ single mutant, which had a more severe
phenotype than the mds3/ mutant (Fig. 2A, compare lanes
2, 4, and 5). In Spider medium, the mds3/ sit4/ double
mutant also behaved similarly to the sit4/ single mutant.
However, the mds3/ single mutant had a more severe phe-
notype, indicating a dominant effect of the sit4/ mutation
(Fig. 2B, compare lanes 2, 4, and 5). These results demonstrate
that the mds3/ sit4/ mutant does not have transcriptional
defects beyond that of the single mutants, suggesting Mds3 and
Sit4 act in the same pathway. However, the addition of rapa-
mycin did not restore CDC19, RPS26A, and TEF1 expression
in the mds3/ sit4/ double mutant (Fig. 2A, lanes 12, 14,
and 15, and B, lanes 7, 9, and 10), although it did restore
GAP2 expression (Fig. 2A, lanes 10 and 15). Rapamycin also
did not rescue the hyphal formation defect associated with
the mds3/ sit4/ double mutant (Fig. 3 and 4A), which
suggests that Mds3 and/or Sit4 has additional parallel func-
tions.
We noted that regardless of pH, wild-type cells grown in
M199 medium express relatively little RPS26A and robust lev-
els of GAP2, suggesting that this medium is a nutrient-poor
medium (Fig. 2A, lane 1). Since TOR responds to nutrient
availability, we asked if Mds3 and Sit4 affect gene expression
in a nutrient-rich environment. Thus, we determined RPS26A
and GAP2 expression in rich YPD medium with or without
rapamycin. Unlike the results obtained for M199 pH 8 and
Spider media (Fig. 2A and B), we observed the robust expres-
sion of RPS26A and no expression of GAP2 in wild-type cells,
and cells lacking Mds3 and/or Sit4 behaved similarly (Fig. 2C,
compare lane 1 to lanes 2, 4, and 5). The addition of rapamycin
reduced the expression of RPS26A and promoted the expres-
sion of GAP2 in wild-type cells, as expected if TOR is inhibited
(Fig. 2C, lane 6). The addition of rapamycin had a similar
effect on mds3/, sit4/, and mds3/ sit4/ mutants (Fig.
2C, lanes 7, 9, and 10). Further, this effect is clearly due to
TOR inhibition, as RPS26A and GAP2 expression was similar
in the mds3/ rbp1/ double mutant with and without rapa-
mycin (Fig. 2C, lanes 11 and 12). We noted that GAP2 expres-
sion in the presence of rapamycin was consistently higher in
the mds3/ mutant, and that this increase was SIT4 depen-
dent. This is in contrast to the results observed in M199 pH 8
medium, where GAP2 expression in the mds3/ mutant in
the presence of rapamycin appears to be Sit4 independent.
These results suggest that M199 medium is a more nutrient-
poor medium than YPD and suggest that Mds3 and Sit4 con-
tribute to the regulation of TOR-dependent targets in nutri-
ent-poor conditions.
Mds3 promotes rapamycin sensitivity. Since rapamycin res-
cued the filamentation defects of the mds3/ and the sit4/
mutants, we wanted to determine if these mutations affected
rapamycin sensitivity in C. albicans. On YPD medium, the
wild-type, mds3/, and mds3/ MDS3 strains showed sim-
ilar rapamycin sensitivities, but the sit4/ mutant was resis-
tant to rapamycin (Fig. 7A). The complementation of the
FIG. 7. Mds3 and TOR pathway members have altered rapamycin resistance. (A) C. albicans wild-type (DAY185), mds3/ (DAY1118),
sit4/ (DAY972), sit4/ SIT4 (DAY973), mds3/ MDS3 (DAY1119), and mds3/ sit4/ (DAY1233) strains were serially diluted in PBS
and spotted onto YPD or Spider media with or without rapamycin. (B) S. cerevisiae wild-type (DAY1208), mds3 PMD1(DAY1209), MDS3 pmd1
(DAY1210), and mds3 pmd1 (DAY1211) strains were serially diluted in PBS and spotted onto YPD or Spider media supplemented with or
without rapamycin. Plates were photographed after 48 or 72 h of growth at 30°C. (C) The C. albicans strains listed for panel A were serially diluted
in PBS and spotted onto YPD or YPD supplemented with 150 mM LiCl or were buffered at pH 6 or 9. Growth was scored after 48 h of incubation
at 30°C.
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sit4/ mutant restored rapamycin sensitivity to wild-type lev-
els. This result for the sit4/ mutant is in sharp contrast to the
situation in S. cerevisiae, where the sit4 mutant is sensitive to
rapamycin and this sensitivity can be rescued by C. albicans
SIT4, suggesting that Sit4 is functioning similarly in the two
organisms (14, 46). These results indicate that MDS3 does not
affect rapamycin sensitivity in rich medium, and that unlike the
case for S. cerevisiae, Sit4 function promotes rapamycin sensi-
tivity in C. albicans.
Since Mds3 appears to promote TOR-dependent responses
in nutrient-poor conditions, we considered that Mds3 affects
rapamycin sensitivity on nutrient-poor medium. Indeed, while
wild-type cells were sensitive to 5 nM rapamycin on nutrient-
poor Spider medium, the mds3/ mutant was resistant (Fig.
7A). Similar results were observed for the sit4/ mutant. The
mds3/ sit4/ double mutant behaved like the sit4/ single
mutant on both media, suggesting that Sit4 and Mds3 do not
make independent contributions to rapamycin sensitivity. These
results demonstrate that Mds3 and Sit4 promote rapamycin sen-
sitivity in C. albicans and support the idea that different nutrient
conditions have distinct constraints on the TOR pathway and the
function of Mds3 and Sit4 in the TOR pathway.
Since the function of Sit4 in S. cerevisiae promotes rapamy-
cin resistance (14), we predicted that the function of Mds3 in
S. cerevisiae would be similar. To test this hypothesis, we
determined the rapamycin sensitivity of congenic wild-type,
mds3, pmd1 (an MDS3 paralog), and mds3 pmd1 S. cer-
evisiae strains (Fig. 7B). On rich medium, the wild type and
pmd1 mutant grew similarly in the presence of rapamycin,
and the mds3 and mds3 pmd1mutants were more sensitive
to rapamycin. Similar results were observed in nutrient-poor
Spider medium; however, we noted that the mds3 pmd1
double mutant grew extremely poorly on this medium (Fig.
7B). Since the rapamycin sensitivities of the mds3 and mds3
pmd1 mutants were similar and since the pmd1 mutant did
not confer rapamycin sensitivity, we conclude that Mds3, but
not Pmd1, functions in the TOR pathway. Cells lacking Sit4 or
Mds3 have similar phenotypes in relation to rapamycin sen-
sitivity; however, these phenotypes are disparate between S.
cerevisiae and C. albicans. Thus, we conclude that Mds3 and
Sit4 function similarly in C. albicans and S. cerevisiae but that
the effect of these functions has changed since C. albicans and
S. cerevisiae split evolutionarily.
Because the mds3/ and sit4/ mutants share a number
of phenotypic traits, we wanted to determine if the sit4/
mutant had other mds3/-dependent phenotypes (18). While
the sit4/ mutant has a slight growth defect on YPD, YPD
plus LiCl, or YPD pH 6 medium, the sit4/ mutant had a
severe growth defect on YPD pH 9 medium that was rescued
by the reintroduction of a wild-type copy of SIT4 (Fig. 7C). The
mds3/ sit4/ double mutant grew more poorly on both
YPD and YPD pH 9 medium than either single mutant (Fig.
7C), supporting the idea that Mds3 and Sit4 have some inde-
pendent functions. The mds3/ sit4/ double mutant grew
similarly to the mds3/ mutant on LiCl medium, suggesting
that Sit4 does not play a role in response to this stress medium.
These results support a model in which Mds3 and Sit4 function
similarly in the TOR pathway but are not completely depen-
dent.
Mds3 and Sit4 physically interact. Mds3 was identified as a
protein that interacts with Sit4 in an S. cerevisiae proteomic
screen (27, 28). Since we have demonstrated a strong genetic
interaction between Mds3 and Sit4, we tested whether Mds3
and Sit4 can indeed physically interact. Thus, we generated a
strain carrying a functional C-terminal 13 Myc-tagged SIT4
allele and then introduced a functional MDS3 allele containing
the 3 HA epitope. Whole-cell extracts of cells grown in M199
pH 8 medium were immunoprecipitated with -HA and
separated by SDS-PAGE. Sit4-Myc was detected in similar
amounts in whole-cell extracts from strains with and without
Mds3-HA (Fig. 8). In -HA immunoprecipitates from cells
containing Mds3-HA, Sit4-Myc was pulled down. Sit4-Myc was
not detected in anti-HA immunoprecipitates in the absence of
Mds3-HA, demonstrating that Sit4-Myc is associating specifi-
cally with Mds3-HA. Similar results were observed in whole-
cell extracts from cells grown in YPD, indicating that this
interaction is not dependent on nutrient availability (Fig. 8).
Thus, Mds3 and Sit4 physically interact, demonstrating that
Mds3 is a member of the TOR pathway.
DISCUSSION
Growth and morphogenesis is controlled by numerous signal
transduction pathways, which respond to diverse environmen-
tal cues. The TOR pathway is a key regulator of growth and
morphogenesis in eukaryotes, and in C. albicans, the TOR
pathway governs the yeast-to-hyphal morphogenetic transition,
which is critical for pathogenesis (14, 77). Microarray analyses
suggested that MDS3 is a member of the TOR pathway in C.
albicans, and this idea was supported by genetic, pharmacolog-
ical, and biochemical approaches. Thus, Mds3 represents a
new member of the TOR morphogenetic pathway.
How does Mds3 contribute to the TOR pathway? Mds3 is a
1,383-amino-acid protein with predicted Kelch repeats in the
N-terminal region but no other obvious motifs and functional
domains (18). Kelch repeats form a -propeller structure that
functions as a protein-protein interaction domain and is found
in an array of proteins, including cytoskeletal proteins and
signal transduction proteins (2, 25, 34, 50). To the best of our
knowledge, Mds3 represents the first Kelch repeat protein
associated with the TOR pathway. However, two components
of the TOR complex, Lst8 and Kog1 (GL and Raptor in
FIG. 8. Mds3 and Sit4 interact physically. C. albicans Sit4-Myc-
tagged (Sit4-M) strains with and without Mds3-HA (Mds3-H)
(DAY1236 and DAY1235, respectively) were grown in M199 (pH 8)
and YPD. An aliquot of the whole-cell extracts (WCE) was separated
by SDS-PAGE, and an aliquot was incubated with anti-HA beads,
centrifuged, washed, and eluted (IP) prior to SDS-PAGE. Blots were
probed with anti-HA first, stripped, and then probed with anti-Myc.
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mammalian systems), contain WD-40 domains, which also fold
into -propeller structures (9, 31, 41, 42, 49). Thus, we propose
that Mds3 acts as a scaffold to facilitate interactions between
TOR pathway members to control morphogenetic processes in
C. albicans.
Based on our results, which include the transcriptional and
morphological similarities between the mds3/ and sit4/
mutants that are rescued by rapamycin and the interaction
between Mds3 and Sit4, we propose two models to explain how
Mds3 acts in the TOR pathway (Fig. 9). First, Mds3 may act
upstream of TOR as a member of a nutrient-sensitive complex,
such as the one composed of Raptor, GL, and mTOR (41,
42). Support for this model comes from the fact that rapamy-
cin, which inhibits TOR kinase activity, rescues the transcrip-
tional defects and morphogenetic defects associated with the
mds3/ mutant (Fig. 2 to 4). Further, the rapamycin-medi-
ated rescue of the mds3/mutant is lost with the introduction
of a TOR1-1 allele or the loss of Rbp1 (Fig. 2 and 5). Based on
these data, Mds3 appears to act upstream of TOR. How-
ever, for this model to be accurate, Mds3 interacts indirectly
with Sit4.
How could Mds3 function upstream of TOR? One possibil-
ity is that Mds3 modulates the interaction of Kog1 and Lst8,
Raptor and GL in mammalian systems, with TOR. GL
promotes TOR kinase activity, and Raptor-GL constitutively
interacts with mTOR. However, Raptor-GL-mTOR interac-
tion is affected by nutrient signals (41). Under nutrient-poor
conditions Raptor-mTOR interaction is stabilized, which in-
terferes with the GL stimulation of mTOR (42). In yeast,
Kog1-Lst8 interaction with Tor1 does not appear to be affected
by nutrient status (49). This led to the hypothesis that an
additional factor, such as Mds3, is involved that affects the
activity of Kog1 and/or Lst8 on Tor1.
An alternative model is that Mds3 acts downstream of Tor1
to promote starvation responses when Tor1 is inactive (Fig. 9).
Support for this model comes from the fact that the sit4/
mutant has transcriptional and morphological defects similar
to those of the mds3/ mutant, and that these defects are
rescued by rapamycin (Fig. 2 to 5). Additionally, both mds3/
and sit4/ mutants are sensitive to alkaline pH (Fig. 7C).
Since rapamycin inhibits TOR kinase activity, these results
suggest that the transcriptional and morphogenetic defects as-
sociated with the mds3/ and sit4/ mutants are due to an
increase in TOR kinase activity or TOR kinase-dependent
activities, and that reduced kinase activity by rapamycin is
sufficient to rescue the sit4/ and mds3/ mutants. Finally,
the fact that Mds3 and Sit4 coimmunoprecipitate suggests that
these proteins interact within the same complex either directly
or indirectly. One potential problem for this model is the
restoration of GAP2 expression by rapamycin in the mds3/
mutant (Fig. 2). However, GAP2 expression also is rescued by
rapamycin in the sit4/ mutant. Thus, additional PP2As,
which are activated by rapamycin treatment, may promote the
expression of GAP2 independently of Mds3 or Sit4. A similar
phenomenon has been described for S. cerevisiae (11, 29, 69).
Finally, we noted that the TOR1-1 allele and mds3/ muta-
tion had a synergistic effect, which generally suggests parallel
pathways. However, the TOR1-1 allele and similar alleles have
altered functions in both S. pombe and mammalian systems
(55, 73, 75), and we find that TOR1-1 confers growth defects in
FIG. 9. Models of Mds3 as a TOR pathway member. (A) Mds3 as an upstream negative regulator of TOR (left). The loss of Mds3 leads to
the increased the expression of genes involved in translation and the increased repression of Sit4 and less expression of the NCR genes (middle).
This loss of negative regulation can be restored with rapamycin (right). (B) Mds3 as a downstream member of the Sit4-dependent pathway
inhibited by TOR. This Sit4-dependent pathway inhibits the expression of RP synthesis genes and promotes the expression of NCR genes (left).
The loss of Mds3 (or Sit4) leads to the increased expression of genes involved in translation and the decreased expression of the NCR genes
(middle). Rapamycin inhibits TOR activation, restoring RP synthesis expression by reduced TOR kinase function. NCR expression also is restored,
although this mechanism is not yet understood (right).
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the absence of a wild-type TOR1 allele (Fig. 5A and 6B). Thus,
we propose that the TOR1-1 mds3/ synergism reflects de-
fective kinase function in Tor1-1, which exacerbates the TOR
pathway defects associated with the mds3/ mutant.
How could Mds3 function downstream of TOR? One pos-
sibility is that Mds3 acts as a scaffold bridging TOR activity to
its effectors. For example, Sit4 activity is dependent upon its
association with Tap42 and several Sit4-associated proteins
(SAPs), and Mds3 may govern these associations (20, 22, 51).
Mds3 may facilitate or stabilize these interactions to promote
Sit4 activity. Support for this idea comes from large-scale pro-
tein-protein interaction analyses that identified Sap185, a Sit4
regulatory protein, as an Mds3 binding partner (20, 27, 28, 51).
Mds3, TOR, and nutrient sensing. TOR kinase activity is
controlled by nutrient availability (12, 20, 41, 66). In nutrient-
rich conditions, TOR kinase activity is stimulated, leading to
the activation of growth processes and the inactivation of star-
vation responses. In starvation conditions, TOR kinase activity
is inhibited, preventing the activation of growth responses and
leading to the activation of starvation responses. Here, we
found that wild-type cells promote the expression of RPS26A
and repression of GAP2 when grown in YPD but promote the
expression of RPS26A, although to reduced levels compared to
those for YPD, and GAP2 when grown in M199 (Fig. 2). This
suggests that M199 is nutrient poor compared to YPD. Fur-
ther, wild-type cells divide slower in M199 pH 8 medium than
in M199 pH 4 medium, suggesting that M199 pH 8 is more
poor than M199 pH 4 medium. The latter growth difference can
be explained by the inhibition of plasma membrane transporters
and the dependence on the endocytic uptake of nutrients in alkali
environments (57, 71, 76). Thus, YPDM199 pH 4M199 pH
8 in nutrient availability, and cells grown in these media may
require different levels of TOR kinase activity.
We found that the mds3/ and sit4/ mutants did not
affect the expression of TOR-dependent genes when grown in
YPD, as expected if Mds3 and Sit4 promote TOR-dependent
starvation responses (Fig. 2). In M199 pH 8 medium and Spi-
der medium, the mds3/ and sit4/ mutants had similar
defects, suggesting that both media are nutrient poor and re-
quire TOR-dependent starvation responses. In M199 pH 4
medium, the mds3/ and sit4/ mutants did not repress
CDC19, RPS26A, or TEF1, nor did they induce GAP2 to wild-
type levels, supporting the idea that M199 pH 4 medium is a
semistarvation medium that requires some level of the TOR-
dependent starvation response. In M199 pH 4 medium, the
sit4/ mutant clearly had a more severe defect in the repres-
sion of CDC19 and RPS26A and induction of GAP2 than the
mds3/ mutant. This represents the first demonstration that
Sit4 negatively regulates RP synthesis and is in contrast to work
with S. cerevisiae, which suggests that Sit4 does not govern RP
synthesis (23, 67). However, these results suggest that Sit4
plays a more general role in promoting TOR-dependent star-
vation responses than Mds3. For example, Sit4 may be re-
quired under both semistarvation and starvation conditions,
whereas Mds3 may function only under starvation conditions.
This idea is supported by the fact that the mds3/ mutant was
resistant to rapamycin in nutrient-poor medium but not in rich
medium, whereas the sit4/ mutant was resistant to rapamy-
cin in both media (Fig. 7A).
Mds3 function in C. albicans and S. cerevisiae. MDS3 was
first identified in S. cerevisiae as a multicopy suppressor of the
mck1 sporulation defect and subsequently was identified as a
regulator of the C. albicans yeast-to-hypha transition (5, 18).
These morphogenetic processes are promoted by neutral-alka-
line environmental pH, which led to the idea that Mds3 is a pH
response regulator that is similar to Rim101. This idea was
supported by the fact that Mds3 is required for wild-type
growth at alkaline pH (18). However, Mds3 also is required for
chlamydospore and biofilm formation in C. albicans, neither of
which require neutral-alkaline pH (60, 65). We also found that
the mds3/ mutant has a slight growth defect on rich me-
dium, which is acidic, and our microarray studies demonstrated
that the mds3/ mutant showed transcriptional changes at
both acidic and alkaline pH (Fig. 1 to 3A and 6 and Tables 3
and 4; also see Table S1 in the supplemental material). Thus,
Mds3 clearly plays a broader role than neutral-alkaline pH
regulation in C. albicans, and we propose that the morphoge-
netic defects observed in the mds3/ mutant reflect defects in
general cellular processes that also are required for growth and
filamentation at alkaline pH.
In S. cerevisiae, Mds3 and Pmd1 are proposed to act up-
stream of or in parallel to the Ras/PKA pathway (5, 54), be-
cause the sporulation defect of the mds3 pmd1 double mu-
tant was rescued by the hyperactive RAS2V19 allele (5).
However, several lines of evidence suggest that Mds3 is un-
likely to function upstream of Ras independently of TOR.
First, the hyperactive RAS2V19 allele rescues TOR pathway
mutants in S. cerevisiae, suggesting that Ras2 acts in parallel or
downstream of the TOR pathway (14, 67, 81). Second, the
filamentation defect of the ras1/ mutant is not rescued by
rapamycin, unlike the mds3/ mutant (Fig. 7 and reference
26, 45). Third, we found that both the sit4 and mds3 mutants
are sensitive to rapamycin in S. cerevisiae. Thus, we propose
that Mds3 acts in the TOR pathway in both S. cerevisiae and C.
albicans, but that the hyperactive RAS2V19 allele is able to
bypass this by acting either in parallel or downstream of TOR.
Why does S. cerevisiae encode two MDS3 paralogs? In S.
cerevisiae, phenotypes associated with the mds3 mutant are
masked by the functionally redundant PMD1 (5, 18). However,
we found that the S. cerevisiae mds3 mutant, like the sit4
mutant but not the pmd1 mutant, was sensitive to rapamycin,
which is the first demonstration that Mds3 and Pmd1 are not
completely redundant in S. cerevisiae. In C. albicans, the
mds3/ and sit4/ mutants behave similarly; however, our
results suggest that Mds3 has Sit4-independent functions.
First, the mds3/mutant is sensitive to high concentrations of
LiCl, whereas the sit4/ mutant is not (Fig. 7C and reference
18). Second, the mds3/ sit4/ double mutant has more
severe growth defects on YPD and at alkaline pH than either
single mutant (Fig. 7C). Third, the filamentation defect of the
mds3/ sit4/ double mutant is not rescued by rapamycin
(Fig. 3 and 4). Thus, in C. albicans, Mds3 has Sit4-dependent
and -independent function. This raises the interesting possibil-
ity that in S. cerevisiae, Mds3 governs the Sit4-dependent func-
tions, rapamycin sensitivity, and Pmd1 governs the Sit4-inde-
pendent functions. It is not yet known if Sit4-independent
functions of Mds3 in C. albicans occur through the TOR path-
way or completely independent of the TOR pathway.
While Mds3 appears to act in the TOR pathway in both C.
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albicans and S. cerevisiae, our results have demonstrated that
the roles of the TOR pathway in these organisms have di-
verged. In S. cerevisiae, sporulation requires both nitrogen and
carbon starvation and is negatively regulated by Mds3. This
suggests that Mds3 functions as a positive regulator of the
TOR pathway (5, 54). However, we have clearly shown that
Mds3 functions as a negative regulator of the TOR pathway in
C. albicans during starvation conditions. Thus, while the TOR
pathway is mechanistically similar in C. albicans and S. cerevi-
siae, the signals coming in to and/or responses coming out of
the TOR pathway appear to be distinct. This idea is supported
by the rapamycin resistance observed for the mds3/ and
sit4/ mutants in C. albicans compared to the sensitivity ob-
served for these mutants in S. cerevisiae (Fig. 7B and reference
14, 46). Regardless, several signal transduction pathways have
been identified that, while mechanistically similar, lead to dis-
tinct responses in C. albicans and S. cerevisiae, which is not
surprising given the 
300 million years of evolutionary dis-
tance between these organisms (37, 39, 52, 70).
Despite the fact that rapamycin initially triggered interest
because of its antifungal properties against C. albicans (72), the
TOR pathway has received relatively little attention in this
organism. In fact, most work has focused on the role of TOR
in multicellular organisms in processes as diverse as angiogen-
esis and embryogenesis. However, TOR appears to have con-
served functions in growth and stress responses in both multi-
cellular and unicellular eukaryotes (64, 79). Our studies
demonstrate that the kelch repeat protein Mds3, which pro-
motes morphogenetic processes critical for pathogenesis, such
as the yeast-to-hypha transition and biofilm formation, is a new
member of the TOR pathway (15, 44, 59). Our study repre-
sents the first example in which a kelch repeat protein has been
implicated in the TOR pathway and raises the possibility that
an Mds3-like protein exists in mammalian systems to promote
TOR-dependent responses.
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